Julie Kim, currently president of Takeda’s U.S. business unit, will succeed him, making her one of the few female chief executives in the pharma industry.
The company blamed lower than expected Q4 returns on its stop-loss insurance business that insures employers from catastrophically high medical claims.
By Bob Herman
More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.